Cargando…
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
Viral replication and transmissibility are the principal causes of endemic and pandemic disease threats. There remains a need for broad-spectrum antiviral agents. The most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses. Altho...
Autores principales: | Tripp, Ralph A., Martin, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955960/ https://www.ncbi.nlm.nih.gov/pubmed/35337018 http://dx.doi.org/10.3390/v14030612 |
Ejemplares similares
-
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
por: Murray, Jackelyn, et al.
Publicado: (2022) -
Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020) -
Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication
por: Mathew, Cynthia, et al.
Publicado: (2021) -
Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
por: Murray, Jackelyn, et al.
Publicado: (2021) -
Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis
por: Tripp, Ralph A.
Publicado: (2013)